PIK3CA and breast carcinoma: Berns et al. have also suggested that oncogenic mutations of PIK3CA may render breast cancers more resistant to treatment with Trastuzumab [47], and Eichhorn et al. have further shown that mutational activation of PIK3CA can similarly render cells more resistant to the recently approved anti-HER2 agent Lapatinib.